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bleeding plus hemorrhagic
diathesisTo the Editor,
We read with great interest the review article by Drs Wong Kee
SongandBaron.1 Theydiscussedbrilliantly the approach toprocedur-
ally induced bleeding, particularly during endoscopic interventions.
Patients with hemorrhagic diathesis or the anticoagulated patients
undergoing endoscopic interventions represent a further clinical
challenge. Bleeding risk associated with hemorrhagic diathesis
and tissue damage due to endoscopic intervention has increased.
Management of this clinical state is usually difﬁcult. Typical
bleeding-pronecases suchasdental extractions, colonoscopy, andco-
lon resection have been treatedusing standard hemostaticmethods.2
The authors mentioned a novel topical hemostatic agent of plant
origin, namely Ankaferd hemostat (ABS), in their review. Although
the statement about ABS is completely true, the cited reference [15]
seems to be improper.1 We would like to point out the recent
experience with ABS for the management of clinical bleeding plus
hemorrhagic diathesis.3–7 ABS affects cellular hemostasis via vital
erythrocyte aggregation and formation of a protein network with
ﬁbrinogen gamma and prothrombin.3,6 Therefore, ABS is effective in
bothbleeding individualswithnormal hemostaticparameters andpa-
tients with deﬁcient primary and/or secondary hemostasis.3,7
Controlled clinical trials indicated the safety and efﬁcacy of ABS for
the topical management of a wide variety of bleeding problems.
Cakarer and coworkers5 disclosed thehemostatic effects of ABSduring
dental extractions in patients on antithrombotic therapy. Likewise,
ABS is a very useful agent for the management of gastrointestinal
bleeding and many other symptoms with or without bleeding diath-
esis.3–7 The ability of ABS to induce the formation of a protein network
not only makes it an effective hemostatic agent, but also confers anti-
infective, antineoplastic, and healing modulator properties to the
extract. Future controlled studies are needed to shed further light on
theexpanding spectrumofABSeffects inhemostasis and relatedareas.
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We appreciate the interest of Purnak et al. regarding our manu-
script on managing procedure-related bleeding.1 We agree that
bleeding in the setting of underlying bleeding diathesis is particu-
larly difﬁcult to manage and also appreciate the insight into the
use of the ankaferd hemostat (ABS) as a topical therapy in this
setting. Unfortunately, this agent is not available to all endoscopists
Gastrointestinal Intervention 2013 2(2), 127–128128since it is not approved in many countries. As we mentioned, other
topical hemostatic agents are currently being evaluated and may
also be useful for managing procedural-related bleeding in the
setting of underlying coagulopathies. With the advent of newer
antithrombotic agents, such topical therapies are increasingly
important, since the new, non-Vitamin-K anticoagulants are not
reversible.2,3 Additionally topical therapy is preferred to complete
reversal of anticoagulationdue to the risk of serious systemic throm-
boembolic complications, especially in the setting of mechanical
heart valves. Additional studies using topical agents for bleeding
in the setting of bleeding diatheses are eagerly awaited, especially
when anticoagulants and antiplatelet agents are not rapidly and
completely reversed.References
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